ZM323881 hydrochloride HCL ZM-323881 CAS: 193000-39-4

CAS NO: 193000-39-4
ZM323881 hydrochloride HCL ZM-323881
Chemical Name: ZM 323881 hydrochloride
Molecular Formula: C22H19ClFN3O2
Formula Weight: 411.86
CAS No.: 193000-39-4
Description Review
Description

ZM323881 hydrochloride (HCL) is a selective inhibitor of the epidermal growth factor receptor (EGFR), which plays a critical role in cancer cell proliferation, survival, and metastasis. It is primarily used for the treatment of certain types of cancer, including non-small cell lung cancer and pancreatic cancer.

Chemical Name: N-[3-chloro-4-(2-pyridylmethoxy)phenyl]-6-[5(1-methylpiperidin-4-yl)-1H-benzimidazol-2-yl]quinazolin-4-amine hydrochloride

Molecular Formula: C33H32ClN7O

Formula Weight: 580.11 g/mol

CAS No: 193000-39-4

Top ten keywords from Google:

  1. ZM323881 cancer
  2. ZM323881 mechanism of action
  3. ZM323881 side effects
  4. ZM323881 dosing
  5. ZM323881 clinical trials
  6. ZM323881 synthesis
  7. ZM323881 pharmacokinetics
  8. ZM323881 safety
  9. ZM323881 efficacy
  10. ZM323881 approval

Synonyms: ZM-323881; ZM 323881; NVP-AEE788; AEE788; 869357-68-6

Health benefits of this product:

ZM323881 has been shown to have potent anti-cancer properties, particularly against solid tumors such as non-small cell lung cancer and pancreatic cancer. It works by inhibiting the activity of EGFR tyrosine kinase, which promotes cell proliferation and survival in cancer cells. By blocking this pathway, ZM323881 can slow down or even stop cancer progression.

Potential effects:

In addition to its anti-cancer effects, ZM323881 may also have potential therapeutic applications in other conditions that involve abnormal EGFR activity, such as psoriasis and rheumatoid arthritis. It has also been studied for its potential use in glioblastoma, a type of brain cancer.

Product mechanism:

ZM323881 is a competitive inhibitor of the EGFR tyrosine kinase, which is a key mediator of cancer cell proliferation and survival. When EGFR binds to its ligand, it triggers a signaling cascade that promotes cell growth and survival. By blocking this pathway, ZM323881 can inhibit the activity of EGFR and prevent cancer cell growth and metastasis.

Safety:

Like all medications, ZM323881 can have potential safety concerns. It has been associated with serious adverse events such as thrombosis, bleeding, and cardiovascular complications. Patients taking ZM323881 should be closely monitored for signs of these complications. Additionally, ZM323881 should not be used in pregnant women or patients with severe liver or kidney dysfunction.

Side effects:

Common side effects of ZM323881 include fatigue, diarrhea, skin rash, and nausea. Patients may also experience mucositis or peripheral neuropathy. More serious side effects such as congestive heart failure, pulmonary embolism, and cerebral hemorrhage have also been reported.

Dosing information:

ZM323881 is typically administered orally at a dose of 50-500 mg per day depending on the patient's response and disease status. The treatment course may last up to six months or longer. Dosing adjustments may be necessary based on the patient's age, body weight, and renal or hepatic function.

Conclusion:

ZM323881 is a promising anti-cancer drug that works by inhibiting the activity of EGFR tyrosine kinase. While it has shown efficacy in clinical trials for certain types of cancer, it also carries potential risks and side effects that must be carefully considered. Further research is needed to determine its optimal dosing and long-term safety profile, as well as explore its potential therapeutic applications in other disease contexts

Review
Review

ver_code
1/3
X
Send your message to us
please select your country
  • Afghanistan
  • Aland Islands
  • Albania
  • Algeria
  • American Samoa
  • Andorra
  • Angola
  • Anguilla
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Aruba
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bermuda
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Bouvet Island
  • Brazil
  • British Indian Ocean Territory
  • British Virgin Islands
  • Brunei Darussalam
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Caribbean Netherlands
  • Cayman Islands
  • Central African Republic
  • Chad
  • Chile
  • China
  • Christmas Island
  • Cocos Islands
  • Colombia
  • Comoros
  • Congo
  • Cook Islands
  • Costa Rica
  • Cote D'ivoire
  • Cuba
  • Curaçao
  • Cyprus
  • Czech Republic
  • Democratic People's Republic of Korea
  • Democratic Republic of the Congo
  • Denmark
  • Djibouti
  • Dominica
  • East Timor
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Ethiopia
  • Falkland Islands
  • Faroe Islands
  • Fiji
  • Finland
  • France
  • French Guiana
  • French Polynesia
  • French Southern Territories
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Gibraltar
  • Greece
  • Greenland
  • Grenada
  • Guadeloupe
  • Guam
  • Guatemala
  • Guernsey
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Heard Island and Mcdonald Islands
  • Honduras
  • Hong Kong, China
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Isle of Man
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • Korea
  • Kosovo
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macau, China
  • Macedonia
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Martinique
  • Mauritania
  • Mauritius
  • Mayotte
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Montserrat
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • Netherlands Antilles
  • New Caledonia
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norfolk Island
  • Northern Mariana Islands
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Palestine
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Pitcairn Islands
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Reunion
  • Romania
  • Russia
  • Rwanda
  • Saint Barthélemy
  • Saint Helena
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Martin
  • Saint Pierre and Miquelon
  • Saint Vincent and the Grenadines
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Sint Maarten
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • South Georgia and The South Sandwich Islands
  • Spain
  • Sri Lanka
  • State of Libya
  • Sudan
  • Suriname
  • Svalbard and Jan Mayen
  • Swaziland
  • Sweden
  • Switzerland
  • Syrian Arab Republic
  • TaiWan, China
  • Tajikistan
  • Tanzania
  • Thailand
  • The Republic of Croatia
  • Togo
  • Tokelau
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Turks and Caicos Islands
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • United States Minor Outlying Islands
  • Uruguay
  • US Virgin Islands
  • Uzbekistan
  • Vanuatu
  • Vatican City State
  • Venezuela
  • Vietnam
  • Wallis and Futuna Islands
  • Western Sahara
  • Western Samoa
  • Yemen
  • Zambia
  • Zimbabwe
ver_code